Search This Website

6/2/21

Monoclonal antibodies cocktail therapy given to 38-year-old Kovid patient for the first time in Ahmedabad

Treatment:  Monoclonal antibodies cocktail therapy given to 38-year-old Kovid patient for the first time in Ahmedabad



Symbolic image

This therapy, given to a patient who does not need oxygen, prevents covid from entering the body's cells.
Monoclonal antibodies to cassirivimeb and imdevimeb are given to the patient in cocktail therapy



A 38-year-old patient with diabetes has been given monoclonal antibody cocktail therapy by Sims Hospital in Ahmedabad. Importantly, this therapy prevents the covid from entering the body's cells, so mild or severe symptoms in the early stages of the covid are given to patients who do not need oxygen as well as to high-risk patients, but are not recommended for patients with moderate or severe covid disease. .

ALSO READ 

Gujarat board exam will also be canceled


The head of the infectious disease department at Sims Hospital, Dr. Surabhi Madan said that the introduction of monoclonal antibody cocktail therapy for MVD patients with Kovid-19 has just started last week. We then gave a 38-year-old patient with covid symptoms with hospitalized diabetes the cockroach therapy of monoclonal antibodies to casirivimeb and imdevimeb. Our hospital in Ahmedabad has started this treatment for the first time. This therapy is given to high-risk patients in the early stages of Kovid-19 infection. Importantly, in the year 2020, such treatment was given to former US President Trump.

Also read 

Wednesday Horoscope


The head of the infectious disease department at Sims Hospital, Dr. According to Surabhi Madan, the launch of Monoclonal Antibodies Cocktail Therapy for Mild Patients of Kovid-19 has just started last week. We then gave a 38-year-old patient with covid symptoms with hospitalized diabetes the cockroach therapy of monoclonal antibodies to casirivimeb and imdevimeb. Our hospital in Ahmedabad has started this treatment for the first time. This therapy is given to high-risk patients in the early stages of Kovid-19 infection. Importantly, in the year 2020, such treatment was given to former US President Trump.

Read in Gujarati news 

Therapy prevents covid cells from entering the body?
This combination drug is intended to prevent SARS-Covid-2 from entering the body's cells. Patients with moderate to severe covid-19 are at risk of infection if there is an increase in covid cells in the body. In particular, high-risk subgroups include patients over the age of 60, patients with severe kidney disease, lung and liver disease, cardiovascular disease, transplant and cancer.

ALSO READ 

Board given time till June 28 to prepare for T20 World Cup, failure to shift to UAE tournament


Cannot be given to patients with acute symptoms
This therapy may be given to patients with mild symptoms of covid, no need for oxygen in the early stages as well as high risk patients, but this treatment is not recommended for patients with covid-19 with moderate or severe symptoms of hypoxia. .

No comments:

Post a Comment